BioMed Research International / 2015 / Article / Tab 1 / Clinical Study
Impact of Dabigatran versus Phenprocoumon on ADP Induced Platelet Aggregation in Patients with Atrial Fibrillation with or without Concomitant Clopidogrel Therapy (the Dabi-ADP-1 and Dabi-ADP-2 Trials) Table 1 Baseline characteristics of the Dabi-ADP-1 and Dabi-ADP-2 study population.
Characteristics Dabi-ADP-1 Dabi-ADP-2 Dabigatran (%) Phenprocoumon (%)
valueDabigatran (%) Phenprocoumon (%) valueAge, years 69 ± 11 70 ± 13 0.89 71 ± 7 76 ± 8 0.06 Woman (%) 14 (40.0) 10 (28.6) 0.31 4 (18.2) 3 (12.5) 0.69 Arterial hypertension (%) 26 (74.3) 24 (68.6) 0.60 21 (95.5) 24 (100) 0.29 Diabetes mellitus (%) 3 (8.6) 9 (25.7) 0.11 5 (22.7) 9 (37.5) 0.28 Hypercholesterolemia (%) 23 (65.7) 23 (65.7) >0.99 18 (81.8) 18 (75.0) 0.57 Prior myocardial infarction (%) 0 (0) 3 (8.6) — 5 (22.7) 10 (41.7) 0.17 Prior bypass surgery (%) 1 (2.9) 1 (2.9) >0.99 3 (13.6) 5 (20.8) 0.70 CHA2 DS2 -VASc score 2.8 ± 1.5 3.2 ± 1.6 0.25 4.0 ± 1.3 4.6 ± 1.0 0.13 Prior stroke (%) 0 (0) 1 (2.9) — 1 (4.5) 1 (4.2) 1.0 Prior TIA (%) 0 (0) 1 (2.9) — 0 (0) 1 (4.2) — Prior bleeding (%) 4 (11.4) 2 (5.7) 0.67 1 (4.5) 3 (12.5) 0.61 Medication at randomization Aspirin (%) 12 (34.3) 13 (37.1) 0.80 20 (90.9) 24 (100) 0.13 Clopidogrel (%) 0 0 22 (100) 24 (100) — Statin (%) 11 (31.4) 18 (51.4) 0.09 20 (90.9) 24 (100) 0.13 PPI (%) 4 (11.4) 7 (20.0) 0.51 5 (25.0) 8 (33.3) 0.55